Cargando…

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value

Detalles Bibliográficos
Autor principal:	Garantziotis, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049565/ https://www.ncbi.nlm.nih.gov/pubmed/21224852 http://dx.doi.org/10.1038/sj.bjc.6606068

Ejemplares similares

Reply: Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
por: Michlmayr, A, et al.
Publicado: (2011)

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
por: Michlmayr, A, et al.
Publicado: (2010)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2013)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
por: Won, Hye Sung, et al.
Publicado: (2020)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
por: Gamucci, T, et al.
Publicado: (2007)

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
por: Venizelos, Andreas, et al.
Publicado: (2022)

Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy
por: Andres, R, et al.
Publicado: (2002)

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients
por: Zhou, Wen-Bin, et al.
Publicado: (2010)

Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors
por: Medioni, Jacques, et al.
Publicado: (2012)

Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial
por: Pizzuti, Laura, et al.
Publicado: (2016)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Knockdown of UbcH10 Enhances the Chemosensitivity of Dual Drug Resistant Breast Cancer Cells to Epirubicin and Docetaxel
por: Wang, Cheng, et al.
Publicado: (2015)

Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients
por: Chen, Lu, et al.
Publicado: (2018)

Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
por: Khoshroo, Sara, et al.
Publicado: (2021)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study
por: Chen, Jianghao, et al.
Publicado: (2013)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
por: Wu, Xian, et al.
Publicado: (2021)

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
por: JÃ¤rvinen, T. A., et al.
Publicado: (1998)

Possible metabolic interaction between docetaxel and ifosfamide
por: Ando, Y
Publicado: (2000)

A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)
por: Kalofonos, Haralabos P., et al.
Publicado: (2004)

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, Luigi, et al.
Publicado: (2009)

Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy
por: Li, Hai, et al.
Publicado: (2019)

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2018)

Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC‐guided dosing in nonsmall cell lung cancer
por: Ma, Yuxiang, et al.
Publicado: (2021)

Docetaxel–induced syndrome of inappropriate antidiuretic hormone secretion
por: Chaudhuri, Tamojit, et al.
Publicado: (2013)

Trastuzumab–Docetaxel Combination Chemotherapy Induced Severe Onychopathy
por: Sonthalia, Sidharth, et al.
Publicado: (2017)

The Predictive Value of 2D Myocardial Strain for Epirubicin-Induced Cardiotoxicity
por: Ben Abdallah, Ichrak, et al.
Publicado: (2020)

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
por: Bartsch, Rupert, et al.
Publicado: (2021)

A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
por: Yao, Xin, et al.
Publicado: (2012)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

The Bayes Factor, a Suitable Complement beyond Values of p<0.05 in Nursing Research and Education
por: Ramos-Vera, Cristian Antony
Publicado: (2021)

Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial
por: Yang, Houpu, et al.
Publicado: (2022)

Plasma Cell Myeloma Initially Presenting as Lung Cancer
por: Cho, Sun Young, et al.
Publicado: (2013)

Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?
por: Yang, Houpu, et al.
Publicado: (2018)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2014)

Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy
por: Danilova, Natalia V, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7tfhjvop55bhgk1a5a7am81i8u